Back To: Home : Featured Technology : Flow Cytometry

CLICK HERE FOR WHAT'S NEW IN:
 

Genisphere, Chembio ink license deal for signal amplification technology
September 2013
SHARING OPTIONS:

HATFIELD, Pa.Genisphere LLC has announced the licensing of its 3DNA Signal Amplification technology to Chembio Diagnostics Inc., which will utilize the technology for its Dual Path Platform rapid diagnostic pipeline tests in hopes of realizing detection limits unique to rapid immunoassays. The agreement follows a feasibility study that demonstrated that the 3DNA Dendrimer could be adapted to Chembio's platform. No financial details were released. The 3DNA Dendrimer technology has been used to improve performance for microarrays, ELISAs, bead-based flow cytometry and lateral flow assays.
 
"Sensitivity, specificity and reproducibility are important features for all diagnostic tests," said Chembio CEO Lawrence Siebert in a statement. "We believe Genisphere's technology can further enhance the performance of our DPP-based assays, leading to commercial success in this competitive marketplace."

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.